Comparing the current results to its competitors, Windtree Therapeutics Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 41.73 %, recorded in the same quarter.
Windtree Therapeutics Inc's Comment on Competition and Industry Peers
The biotechnology industry is highly competitive, with numerous pharmaceutical companies and other firms entering fields related to the company's product candidates. Competition is expected to intensify as companies vie for development resources such as clinical sites and patients. Companies that are first to introduce new products and technologies may gain significant advantages. The company is investing in intellectual property protections, including patents, regulatory exclusivities, and trade secrets, to maintain its competitive position.
October 9, 2024
: Istaroxime, a novel therapeutic agent, has demonstrated promising efficacy in a Phase 2b study focusing on acute heart failure patients experiencing early cardiogenic shock. This article consolidates findings from recent announcements by Windtree Therapeutics and discusses the trial design and outcomes, emphasizing its potential impact in this critically ill patient population. Acute heart failure, especially when complicated by early cardiogenic shock, poses significant risks and has limited treatment options. Windtree Therapeutics has announced key developments regarding istaroxime, a drug anticipated to address this clinical need. Recent reports highlight positive topline results from the Phase 2b SEIS...
September 30, 2024
Heart failure, particularly in the context of early cardiogenic shock (ECS), represents a critical condition affecting millions globally. Traditional treatments have often struggled to effectively manage the complexities associated with this syndrome, where the heart s ability to pump blood is critically impaired. However, recent data emerging from Windtree Therapeutics indicates a viable therapeutic alternative: Istaroxime. This article discusses the findings from the Phase 2b clinical trial highlighting the drug s potential to significantly improve cardiac function, blood pressure, and renal function in heart failure patients experiencing ECS. Methods The Phase 2b study designed by Windtree Therapeutics wa...
September 4, 2024
Windtree Therapeutics Inc. recently achieved a significant milestone by completing enrollment in its Phase 2b study of Istaroxime, a potential treatment for early cardiogenic shock. While the anticipation for topline data, expected in late September 2024, generates excitement in the cardiovascular medical community, the company s financial performance reveals a contrasting narrative. This article seeks to explore both the scientific and financial dimensions of Windtree Therapeutics’ current situation, providing a comprehensive view of its prospects and challenges. Istaroxime and Its Potential Impact Istaroxime is an investigational drug that aims to improve cardiac function during early cardiogenic shock, ...
February 1, 2024
WARRINGTON, Pa., Feb. 01, 2024 - Windtree Therapeutics, a prominent biotechnology company focusing on late-stage interventions for critical cardiovascular disorders, has recently announced the renewal of its partnership with Chang Gung University in Taiwan. This collaboration aims to further scientific research on SERCA2a, an essential target in Windtree s cardiovascular portfolio.Windtree personnel, stationed at their Taipei offices in Taiwan, will actively participate in this renewed scientific alliance. The partnership with Chang Gung University, renowned for its expertise and research capabilities in the field of medical sciences, strengthens Windtree s commitment to advancing therapies for cardiovascula...
January 17, 2024
In an exciting development, Windtree Therapeutics, a biopharmaceutical company specializing in the development of innovative therapeutics for cardiovascular and respiratory diseases, has announced a strategic license agreement with Lees Pharmaceuticals. This collaboration aims to develop and commercialize two groundbreaking product candidates, Istaroxime and Rostafuroxin, in the Greater China/Asia Pacific region. Windtree will not only receive substantial financial benefits but also gain comprehensive support for development, manufacturing, regulatory, and commercialization efforts in the licensed territory.Partnership BenefitsUnder the terms of the agreement, Windtree can potentially receive future mileston...
January 2, 2024
In recent years, there have been significant advancements in the field of cardiovascular medicine, particularly in the treatment of arrhythmias. Windtree Therapeutics, a leading biotechnology company, has announced impressive findings from a new preclinical study involving istaroxime, a pure SERCA2a activator. These findings further strengthen the previously reported clinical data from three Phase 2 studies, shedding light on the potential of istaroxime as a breakthrough treatment option for arrhythmias. This article aims to explore the details of the study and its implications for the future of cardiovascular medicine.Background and Study Design:Arrhythmias, irregular heart rhythms, are a severe health conc...
In the realm of medical advancements, every breakthrough offers new hope for patients and medical professionals alike. One such breakthrough is being pioneered by Windtree Therapeutics, a biotechnology company specializing in developing novel treatments for respiratory and cardiovascular diseases. The company recently announced the commencement of patient dosing in their highly anticipated Phase 2 SEISMiC Extension Study of Istaroxime, a potential game-changer for those suffering from early cardiogenic shock. As we eagerly await the study s results, anticipated in mid-2024, the potential for dose optimization and subsequent Phase 3 trials holds immense promise for cardiac patients worldwide. Un...
Windtree Therapeutics, a renowned biotechnology company, has recently announced the issuance of a groundbreaking patent for a new class of SERCA2a Activators. This development has enormous potential and could revolutionize the treatment of heart failure. Building upon the company s current lead program, this innovative therapy has the capacity to open new avenues for novel treatments, offering hope to millions of heart failure patients worldwide.
Windtree Therapeutics has just made an extraordinary breakthrough in its quest to combat heart failure with the announcement of a newly issued patent for a class of Pure SERCA2a Activators. This pioneering development could truly be a game-changer...
Publicly Traded Peers of Windtree Therapeutics Inc
Iovance Biotherapeutics inc Share Performance
+253.01%
One Year
Iovance Biotherapeutics inc
Profile
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Soligenix Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases. Their business model revolves around leveraging their expertise in developing innovative therapies and securing partnerships and collaborations with academic institutions, government agencies, and other companies to accelerate the development process. Soligenix also strategically seeks funding through grants and licensing deals to support their pipeline and growth initiatives.
Sources:
Windtree Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Windtree Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
